Cagrilintide

Cagrilintide is a long-acting amylin analogue that works differently from GLP-1 agonists. While GLP-1 drugs reduce appetite through the brain and gut, cagrilintide targets amylin receptors — adding an extra layer of appetite suppression. It’s being studied both alone and in combination with semaglutide for potentially even greater weight loss. Supplied as lyophilized powder with ≥98% purity (HPLC-verified).

How It Works

Amylin is a hormone naturally released with insulin after meals. Cagrilintide mimics amylin, activating receptors in the brain’s area postrema. This reduces food intake, slows gastric emptying, and suppresses glucagon release after meals.

Weight Loss Research Data

• Human trial (Phase 2, Lancet 2021): When combined with semaglutide 2.4 mg, cagrilintide helped subjects lose an average of 17.1% of body weight in just 20 weeks — a remarkable result for such a short study period.
• Cagrilintide alone produced 6-10% weight loss depending on dose, showing a clear dose-response relationship.
• The combination with semaglutide was more effective than either drug alone, suggesting complementary mechanisms.
• Reductions in waist circumference, blood pressure, and cholesterol were also reported.

Research Applications

• Amylin receptor pharmacology
• Appetite regulation and satiety signaling
• Combination therapy research for obesity
• Gastric emptying and post-meal glucose control

Product Specifications

• Purity: ≥98% (HPLC)
• Form: Lyophilized powder
• Solubility: Reconstitute in sterile bacteriostatic water

Storage & Handling

• Store lyophilized peptide at -20°C, protected from light and moisture.
• After reconstitution, aliquot and store at -20°C. Avoid repeated freeze-thaw cycles.

Disclaimer: This product is intended exclusively for laboratory and research purposes. It is not a drug, dietary supplement, or food product. Not for human or veterinary use.

What the Internet Says

This is what online communities discuss about this compound. Not medical advice, not a recommendation — just what people are saying. For laboratory research use only.

Community Buzz

Cagrilintide — called “Cagri” — is at the center of one of the most exciting weight loss developments in peptide history. It works through amylin and calcitonin receptors — a completely different brain pathway than Semaglutide or Tirzepatide. While GLP-1s tell your brain “stop eating,” Cagri says “you are full — really, completely full.” The result: you feel satisfied after a few bites, and food just stops being interesting. The killer feature is the combination — CagriSema (cagrilintide + semaglutide) produced 15.6% weight loss at 32 weeks in clinical trials vs just 5.1% for semaglutide alone. That’s nearly triple the effect of Sema monotherapy in half the time of the STEP trial. The community is in a frenzy — people are buying research-grade Cagri and Sema separately and DIY-compounding their own “CagriSema” years before FDA approval. The REDEFINE Phase 3 trial head-to-head against Tirzepatide is the most anticipated weight loss trial in years. The downside: nausea at higher doses (47% rate at 4.5mg/week) is no joke — the community mantra is “titrate slowly, don’t rush, you’ll regret it for a week because the half-life is 7.3 days.”

Why People Are Interested

• Appetite control from a different angle. Works on amylin receptors, not GLP-1 — you can add it to Semaglutide or Tirzepatide for multi-pathway appetite suppression. Users who plateaued on GLP-1s alone say “Cagri made it work again.”
• Triple the weight loss of Semaglutide alone. Clinical data: CagriSema achieved 15.6% vs Sema alone at 5.1% over 32 weeks. The synergy is real and well-documented.
• Once-weekly dosing. 7.3-day half-life means one injection per week — no daily pinning, no complex timing.
• Different side effect experience for some. Users who can’t tolerate GLP-1 nausea sometimes find Cagri’s side effect profile qualitatively different and more manageable.

Popular Combinations

• Cagrilintide + Semaglutide (CagriSema): THE combination — amylin + GLP-1 pathways for synergistic appetite suppression. The most discussed upcoming obesity treatment.
• Cagrilintide + Tirzepatide: Triple-mechanism appetite suppression (GIP + GLP-1 + amylin) — extreme biohacking, no safety data exists.

⚠️ Sourced from public forums (Reddit r/Peptides, r/Biohackers), clinical trial publications (REDEFINE program), and peptide communities. CagriSema is NOT FDA-approved (Phase 3 trials ongoing). DIY CagriSema compounding from research chemicals is legally gray and medically risky. Nausea at higher doses affects nearly half of users at 4.5mg/week. The 7.3-day half-life means overdose symptoms last a full week. Community protocols are experimental. This information is for awareness only.